Huntington's disease (HD) is neurodegenerative disorder caused by a 29 polyglutamine expansion in the N-terminal region of the huntingtin protein (N17). 30
Introduction 46
Huntington's disease (HD) is characterized by the loss of medium spiny neurons 47 in the striatum. The main histopathological hallmark of HD is the misfolding and 48 subsequent intracellular aggregation of a mutant form of huntingtin (HTT) [1] . HTT is 49 a very large protein (~350 kDa), but expression of exon 1 is sufficient to produce HD-50 like features in various cellular and animal models [2] [3] [4] . HTT exon 1 (HTTex1) 51 inflammatory responses, also regulates T3 and S13/S16 phosphorylation and 78 modulates HTT aggregation [30, 37, 39, 41] . While several protein phosphatases 79 control HTT dephosphorylation beyond exon 1 and modulate its toxicity [42] [43] [44] [45] [46] , it is 80 not known which protein phosphatases, if any, regulate phosphorylation of the N17 81 domain. 82
Here, we elucidate the contribution of single N17 phosphorylation events 83 towards HTTex1 oligomerization, aggregation and toxicity. We screened a collection 84 of protein phosphatase chemical inhibitors to identify modulators of HTTex1 85 oligomerization and aggregation in human cells. Inhibition of PP1 prevents HTTex1 86 aggregation but not oligomerization in human cells. In addition, downregulation of 87 PP1 in Drosophila neurons reduces HTTex1 aggregation and increases its toxicity. In 88 total, our findings point to a critical role of T3 phosphorylation in HTTex1 89 aggregation and support the targeting of PP1 for therapeutic interventions in HD. 90 91
Results

92
Single N17 phosphomutants modulate HTTex1 aggregation in human cells 93
In order to investigate the contribution of each phosphorylatable residue within 94 the N17 region (T3, S13 and S16) towards HTTex1 aggregation, we used the BiFC 95 system for the visualization of both oligomeric species and inclusion bodies of 96 HTTex1 in living cells, which we have previously described [47] [48] [49] . In this system, 97 wild type (19Q) or disease-causing (97Q) HTTex1 are fused to non-fluorescent halves 98 of the Venus fluorescent protein ( Fig 1A) . In this system, upon dimerization of 99 HTTex1 fragments, the Venus halves are brought together and reconstitute the 100 functional fluorophore. Therefore, fluorescence is proportional to the extent of 101 HTTex1 dimerization/oligomerization. We introduced point mutations in each of the phosphorylatable residues within the N17, changing these amino acids to either 103 alanine (A mutants, which cannot be phosphorylated -phosphoresistant) or to aspartic 104 acid (D mutants, which mimic the phosphorylated state -phosphomimic). 105 Importantly, these phosphomutants behave like phosphorylated peptides in terms of 106 their aggregation in cell-free systems and primary neuronal cultures [26, 28] . 107
We had previously shown that 97QHTTex1-Venus BiFC pairs oligomerize and 108 aggregate more readily than wild-type 19QHTTex1-Venus BiFC pairs [49] . 109
Strikingly, all single phosphomimic mutations of 97QHTTex1-Venus BiFC constructs 110 (T3D, S13D, S16D) completely abolished the formation of inclusion bodies in human 111 cells ( Fig 1B and C) while the phosphoresistant mutants (T3A, S13A, S16A) behaved 112 similarly to non-mutated 97QHTTex1-Venus BiFC pairs (Fig 1B and C and S1 Fig) . 113
These phenotypes were further confirmed by filter trap assays, where non-mutated 114 97QHTTex1 and phosphoresistant pairs appear as large SDS-insoluble aggregates, as 115 opposed to wild-type 19QHTTex1 and phosphomimic pairs. ( Fig 1D, filter trap (FT)). 116
No differences in oligomerization/fluorescence levels were observed between the 117 phosphomutants, and non-mutated 97QHTTex1, as determined by flow cytometry (S2 118 Fig) . Native-PAGE analyses confirmed that all phosphomutants formed oligomeric 119 species ( Fig 1D) . These results are consistent with a recent report where expanded 120
HTTex1 was shown to exist as tetramers but not monomers [50] . 121
Due to its dynamic nature, phosphorylation usually affects only a fraction of the 122 total pool of any given protein. Thus, we hypothesized that subpopulations or pools of 123 97QHTTex1 with different extents of phosphorylation may co-exist in cells. In order 124 to determine whether 97QHTTex1 fragments with different phosphorylation status 125 interacted in living cells, we took advantage of the unique features of our BiFC 126 system to screen all possible pairwise combinations of phosphomutants and non-mutated 97QHTTex1 control (Table 1) . Combinations of phosphomimic with non-128 mutated 97QHTTex1 oligomerized to the same extent as the non-mutated 129 97QHTTex1 pair, as determined by flow cytometry (S3 Fig) . However, 130 phosphomimic pairs did not form inclusions, independently of the mutated residue 131 (Table 1) . Combinations of phosphomimics with non-mutated 97QHTTex1 (Table 1  132 and Fig 2A and including T3D, S13D or S16D resulted in 0 %, 14.1-22.0 % or 19.8-29 .1 % of cells 135 with inclusions, respectively (Table 1) , which is significantly less than the percentage 136 of cells with inclusions observed with the non-mutated 97QHTTex1 pair (36.1%). In 137 contrast, phosphoresistant pairs generally resulted in an increased percentage of cells 138 displaying inclusions (43.5-48.5% cells with inclusions), with the exception of the 139 S13A/S16A combination (35.3%) (Table 1) . 140
Importantly, the effect of phosphomimic mutants on 97QHTTex1 aggregation 141 appears to be protein-specific (Fig 2) . We and others have recently shown that 142
HTTex1 co-aggregates with alpha-synuclein (aSyn) and Tau, and that these 143 interactions change the aggregation profile of HTTex1 [47, 48, 51, 52] . Combinations 144 of phosphomimic 97QHTTex1 with aSyn BiFC constructs resulted in a residue-145 dependent reduction in the percentage of cells with inclusions, with the T3D/Syn 146 showing no inclusions (Fig 2A, C) . On the other hand, combinations of Tau-Venus 147 plasmids showed the same aggregation pattern independently of the mutated residue 148 (Fig 2A, D) . These observations further support that single N17 phosphomutants 149 modulate HTTex1 aggregation, and that the T3D is the most restrictive modification 150 in preventing HTTex1 aggregation. 151
Increased dynamics of 97QHTTex1 inclusions containing S13 or S16 153 phosphomimic mutants 154
We next analysed the dynamics of 97QHTTex1 inclusions using fluorescence 155 recovery after photobleaching (FRAP). We observed a faster fluorescence recovery in 156 inclusions formed by pairs containing phosphomimic mutants (S13D or S16D) and 157 non-mutated 97QHTTex1 in comparison to inclusions formed exclusively by non-158 mutated 97QHTTex1 ( Fig 3A and 3B , S1-S3 Videos). The phosphoresistant (T3A or 159 S13A)/97QHTTex1 pairs, but not the S16A/97QHTTex1, presented slower 160 fluorescence recovery in inclusions ( Fig 3C) . Phosphomimic-containing inclusions 161 often had less defined boundaries, appearing rather continuous with the cytosolic 162 fluorescence, consistent with areas of more dynamic exchange of HTT protein. 163 Inclusions formed by the S13D/97QHTTex1 combination ( Overall, the results suggest that single phosphorylation events within N17 domain 168 prevent HTTex1 aggregation but not its oligomerization, and that phosphorylation at 169 the T3 residue might play a critical role in modulating HTTex1 aggregation. In 170 addition, our observations support the idea that inclusions might be composed of non-171 phosphorylated HTT or mixtures of non-phosphorylated and phosphorylated pools of 172 molecules, consistent with data indicating that disease-causing HTT is 173 hypophosphorylated in the N17 region [29, 37] . 174
The results above indicate that single N17 phosphorylation can modulate HTTex1 177 aggregation, which is consistent with the idea that N17 phosphorylation might be 178 enhanced by the activation of kinases [30, 37, 39] or, alternatively, by the inhibition of 179 phosphatases. In order to identify protein phosphatases that might mediate HTTex1 180 dephosphorylation, we screened a library of 33 phosphatase chemical inhibitors for 181 their effect on HTTex1 aggregation and oligomerization, using our 97QHTTex1-182
Venus BiFC system (Fig 4, and S1 Table) . We found that inhibitors of PP1/PP2A, 183 CD45, and Cdc25 prevented 97QHTTex1 aggregation as determined by filter trap 184 assay ( Fig 4A) . These results were confirmed by fluorescence microscopy, where we 185 observed that inhibitors for those phosphatases significantly decreased the percentage 186 of cells with inclusions ( Fig 4B) . Interestingly, the decrease in oligomerization upon 187 treatment with these phosphatase inhibitors was much less dramatic than the reduction 188 observed in aggregation levels (B01, B02, B07, B08 and C04). Although a slight 189 reduction in fluorescence/oligomerization was observed for 28 out of the 33 inhibitors 190 assayed, the few exceptions where a striking decrease was observed (C06, D01 and 191 D03) were due to cytotoxicity (S1 Table) . Importantly, cells treated with CD45 192 inhibitors showed reduced levels of HTTex1 expression and increased toxicity (S1 193   Table) , and were therefore excluded from the study. Fig 5B) and T3D ( Fig 5E) mutants formed fewer inclusions than non-mutated 203 97QHTTex1 ( Fig 5A) , while S13D ( Fig 5F) and S16D ( Fig 5G) mutants showed a 204 significantly larger number of aggregates (quantification in Fig 5O) . S13A ( Fig 5C)  205 and S16A ( Fig 5D) showed no difference in the number of inclusions in comparison 206 with non-mutated 97QHTTex1 ( Fig 5O) . In the larval eye imaginal discs, all 207 phosphomutants showed decreased aggregation, with the exception of S13D mutant 208 that formed more inclusions than the non-mutated 97QHTTex1 (S4 Fig) . flies showed a significant decrease in 97QHTTex1 aggregation ( Fig 5H) , while PP2A 220 or string (Cdc25 homologue) downregulation had no effect on 97QHTTex1 221 aggregation (S5 Fig, A and B ). PP1 downregulation prevented 97QHTTex1 222 aggregation in the presence of serine-phosphoresistant mutants (S13A or S16A) ( Fig  223   5J and K), but not T3A, where we did not observe any statistically significant change 224 in the number of aggregates when compared with T3A in the absence of PP1 RNAi 225 ( Fig 5O) . These results indicate that the effect of PP1 RNAi on 97QHTTex1 aggregation might be mostly mediated by T3 phosphorylation. On the other hand, PP1 227 knockdown caused an increased number of aggregates in T3D background, and a 228 reduction in the number of aggregates in S13D and S16D backgrounds ( Fig 5O) . 229
Since HTTex1 does not contain any phosphorylatable residue beyond N17 domain, 230 the increased aggregation observed in the T3D background upon PP1 inhibition 231 suggests that S13 and/or S16 might also be target for phosphorylation to modulate 232 97QHTTex1 aggregation, in our Drosophila model. 233
We next analysed the effect of PP1, PP2A or string RNAi knockdown on 234
HTTex1 toxicity in the Drosophila eye photoreceptor neurons ( Fig 6 and S5 Fig) . the precise molecular mechanisms by which misfolded proteins aggregate and form 247 toxic species remain elusive. Increasing evidence suggests that targeting 248 phosphorylation events in the N17 domain of mutant HTT can influence the 249 pathological function of the protein [28, 30, [36] [37] [38] . However, the significance of single 250 N17 phosphorylation events in HTT oligomerization, aggregation and toxicity is still 251 poorly understood. 252
Here, we report that single N17 phosphorylation can prevent HTTex1 253 aggregation, but not oligomerization. We propose that each residue has a different 254 "strength" in modulating HTTex1 aggregation. Importantly, we found that protein 255 phosphatase 1 can control HTTex1 aggregation and toxicity, suggesting that N17 256 phosphorylation might be mediated by this protein phosphatase. The fact that single 257 N17 phosphorylation events are sufficient to abolish HTTex1 aggregation could be 258 very important from an HD therapeutic perspective, since a single N17 259 phosphorylation could provide a simpler molecular target than double 260
phosphorylation. 261
We show that single phosphomimic mutation in T3, S13 or S16 allow 262 97QHTTex1 to oligomerize but not to form large inclusions in human cells (Fig 1 and  263   S2 Fig) . Double S13/S16 phosphorylation prevents aggregation both in vitro and in 264 vivo, and toxicity in vivo [22, 26] . However, double S13/S16 phosphorylation is less 265 abundant than single phosphorylation events [39] , and may require the overexpression 266 of specific kinases [30] , which may confound therapeutic efforts based on this 267 approach. Although some studies reported on the effect of single S13 or S16 268 phosphorylation events on HTTex1 intracellular localization, they did not focus on 269 HTTex1 oligomerization, aggregation or toxicity [28, 37] . Results from cell-free 270 systems indicate that single S13-or S16-phosphorylated HTTex1 behave similarly to 271 double S13/S16-phosphorylated HTTex1 in terms of aggregation, being unable to 272 form mature fibrils [26] . Our findings in living human cells provide additional 273 biological support for those in vitro studies. 274
The unique properties of our BiFC cellular model allowed us to analyse the 275 relative contribution of each phosphorylatable residue towards HTTex1 276 oligomerization and aggregation. We found that T3D completely abolished 277 97QHTTex1 aggregation in the presence of any other phosphomutant or non-mutated 278 97QHTTex1 molecules, while S13D or S16D only had a partial reduction effect ( Fig  279   2 and Table 1 ). These results, together with the higher abundance of T3-280 phosphorylated pools [39, 40] , highlight the relevance of this residue in modulating 281 the aggregation of HTTex1, and strongly support T3 as a promising target for HD 282 intervention [29] . Our results also suggest that, HTTex1 might be predominantly 283 unphosphorylated under pathological conditions [29, 37] , as phosphoresistant 284 combinations behave more similarly to the non-mutated 97QHTTex1 pair than to the 285 phosphomimics, regarding their aggregation pattern (Fig 1 and Table 1 ). 286
Previous in vitro studies demonstrate that N17 phosphorylation inhibits β-287 sheet conformation of mutant HTTex1 and suppresses its fibrillisation, stabilizing the 288 α-helical structure of the N17 domain which could led to altered aggregation 289 dynamics [41, 53] . In FRAP experiments, we show that combinations of 290 phosphomimic and non-mutated 97QHTTex1 induced the formation of inclusions that 291 were more dynamic, diffuse and fluid than regular 97QHTTex1 aggregates, 292
resembling an intermediate stage between oligomers and mature inclusions (Fig 3, S1 -293 S4 and S6 Videos). Additionally, non-mutated 97QHTTex1 pairs did not aggregate to 294 the same extent as the phosphoresistant combinations ( Fig 1C and Table 1 ). Thus, we 295 propose a model where unphosphorylated HTTex1 fragments oligomerize and form 296
inclusions that grow into mature fibrils until enough phosphorylated HTTex1 297 molecules are intercalated in the structure to interfere with the process, acting as a 298 'brake'. This could explain the existence of aggregates of various sizes and 299
morphologies. 300
Genetic and pharmacological inhibition of PP1 resulted in lower 97QHTTex1 301 aggregation and increased toxicity (Fig 4-6) . Protein phosphatases PP2B/3 302 (Calcineurin), PP2C and PP1/PP2A have been also shown to regulate HTT 303 phosphorylation at several residues beyond exon 1, as well as HTT toxicity [42] [43] [44] [45] [46] . It 304 is important to note that HTTex1 does not contain any phosphorylatable residue 305 beyond the N17 domain and, therefore, any direct effect of protein phosphatases 306 should happen on T3, S13 or S16. Our results indicate that PP1 affects 97QHTTex1 307 aggregation by regulating T3 phosphorylation. In Drosophila dopaminergic neurons, 308 PP1 knockdown in serine-phosphomutant backgrounds leads to a decrease in 309 97QHTTex1 aggregation, regardless the phosphorylation-like state of these residues 310 ( Fig 5O) . Moreover, PP1 RNAi does not cause any further reduction of 97QHTTex1 311 aggregation when co-expressed with T3A mutant. Together, these data suggest that 312 the effect of PP1 inhibition on HTTex1 aggregation is primarily mediated by T3 313 phosphorylation. However, an increase in 97QHTTex1 aggregation is observed when 314 PP1 RNAi is co-expressed with T3D mutant (Fig 5L and O) , indicating that S13 and 315 S16 might also be target for PP1 regulation. Since S13D or S16D increase 316 97QHTTex1 aggregation ( Fig 5F, G and O) , we hypothesize that PP1 modulates S13 317 or S16 phosphorylation upon T3 phosphorylation. In fact, it is likely that different 318 N17 mutations may contribute to subsequent phosphorylation events in other residues. 319
For example, IKK-mediated S16 phosphorylation is facilitated by previous 320 phosphorylation of S13 [30] . 321
Interestingly, the striking decrease in 97QHTTex1 aggregation observed when 322 PP1 RNAi was co-expressed with S13D or S16D mutants versus S13D or S16D alone 323 (no RNAi) ( Fig 5O) , suggests that T3 phosphorylation is dominant over S13 or S16 324 phosphorylation. Our human cell data also supports this hypothesis, since S13D or 325 S16D BiFC combinations with non-mutated 97QHTTex1 still shows aggregates, 326 while T3D BiFC combinations with any other mutant completely abolishes 327 aggregation (Fig 2 and Table 1) . 328
In summary, our results support a strong role for single N17 phosphorylation 329 events on HTTex1 aggregation, dynamics and toxicity, and uncover the regulatory 330 role of PP1 in these events. Ultimately, our study opens novel avenues for the 331 therapeutic targeting of PP1 and N17 phosphorylation in HD. Switzerland). For all experiments, cells were counted and seeded at a density of 347 10,000 cells/cm 2 regardless dish size. Generation of HTTex1-and tau-Venus BiFC constructs was described in detail elsewhere [47, 49] Phosphomimic (T3, S13 or S16 mutated to aspartic acid) and phosphoresistant (T3, 352 S13 or S16 mutated to alanine) constructs were produced by PCR-based site-directed 353 mutagenesis using 97QHTTex1-Venus plasmids as templates. Plasmid transfection 354 was performed by means of the X-tremeGene 9 reagent (Roche diagnostics, 355
Mannheim, Germany), following manufacturer's instructions. Twenty-four hours after 356 transfection, cells were collected and analysed for oligomerization, aggregation and 357 toxicity as described below. Pharmacological inhibition of protein phosphatases was 358 performed using a phosphatase inhibitor library (Enzo Life Sciences, Lausen, 359 Switzerland). Briefly, cells were treated with 33 different phosphatase inhibitors upon 360 transfection of 97QHTTex1 BiFC constructs. Phosphatase inhibitors were dissolved 361 in DMSO and added to culture medium at variable concentrations, according to the 362 IC50 described in manufacturer's instructions (S1 Table) . 363 364
Flow cytometry 365
Cells were washed with Ca 2+ and Mg 2+ free phosphate buffer saline (PBS) (Gibco, 366 Invitrogen, Barcelona, Spain) and collected by trypsinization (0.05% w/v trypsin, 5 367 min, 37ºC) into BD Falcon Round-Bottom tubes (BD Biosciences, San Jose, CA, 368 USA). Cell pellet was resuspended in PBS and analysed by means of a LSR Fortessa 369 flow cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA). Ten thousand cells 370 were examined per experimental group. The FlowJo software (Tree Star Inc., 371
Ashland, OR, USA) was used for data analyses and representation. 372
Fluorescence microscopy and FRAP experiments 374
Images of living H4 cells were acquired using an Axiovert 200M widefield 375 fluorescence microscope equipped with a CCD camera (Carl Zeiss MicroImaging 376 GmbH, Germany). Pictures of a total of 100-150 cells per sample were scored for 377 aggregate quantification using the ImageJ free software (http://rsbweb.nih.gov/ij/). 378 FRAP experiments were performed using a META LSM 510 confocal microscope. 379
Briefly, protein aggregates were focused at the central focal plane and adjusted to 380 avoid pixel saturation. Experiments lasted for 70-150 s, taking one picture every 381 second. After establishing the basal signal, aggregates were bleached using the 488 382 nm laser line at 100% laser transmission on a circular region of interest (ROI) with a 383 diameter of 30 pixels (1.31 µm radius) for 5 s (10 iterations). Fluorescence recovery 384 was then monitored for 60-140 s with LSM software. Images were analysed and 385 prepared for publication by means of the ImageJ free software. 386
387
Immunoblotting 388
Proteins were extracted in native or denaturing conditions according to the 389 requirements of each technique. Briefly, cells were washed with PBS 1X and 390 collected by scraping. Cells were incubated with lysis buffer and sonicated for 10 sec 391 at 5 mA using a Soniprep 150 sonicator (Albra, Milano, Italy). For denaturalizing 392 conditions, the lysis buffer was 1% Triton X-100, 150 mM NaCl, 50 mM Tris pH 7.4, 393
supplemented with a protease inhibitor cocktail (Roche diagnostics, Mannheim, 394
Germany). For native conditions, the lysis buffer was 173 mM NaCl, 50 mM Tris pH 395 7.4, 5 mM EDTA, also supplemented with protease inhibitor cocktail. Proteins were 396 collected after cell lysate centrifugation at 10,000 g for 10 min at 4ºC and quantified 397 by means of the BCA Protein Assay Reagent Kit (Thermo Fisher Scientific Inc., Rockford, IL, USA), following manufacturer's instructions. For SDS-or Native-399 PAGE immunoblotting, 15 µg of total protein extracts were prepared and separated by 400 electrophoresis using a 12% SDS-polyacrylamide gel or a 5% SDS-free-401 polyacrylamide gel, respectively. For denaturing conditions, samples were boiled in 402 standard loading buffer (200 mM Tris-HCl pH 6.8, 8% SDS, 40% glycerol, 6.3% β-403 mercaptoethanol, 0.4% bromophenol blue) for 5 min at 95ºC. For native conditions, 404 extracts were mixed with SDS-and mercaptoethanol free loading buffer (200 mM 405
Tris-HCl pH 6.8; 40% glycerol; 0.4% bromophenol blue) and the boiling step was 406 omitted. Proteins were transferred onto PVDF membranes and blocked with 5% (w/v) 407 non-fat dry milk in Tris-HCl buffer saline-Tween solution (TBS-T) (150 mM NaCl, 408 50 mM Tris pH 7.4, 0.5% Tween-20) for 1 h at room temperature. Membranes were 409 incubated with primary antibodies against HTT (1:500, Millipore, Billerica, MA, 410 USA) and GAPDH (1:30000, Ambion, Austin, TX, USA) as specified. A secondary 411 mouse IgG Horseradish Peroxidase-linked antibody (1:10000, GE Healthcare Life 412
Sciences, Uppsala, Sweden) was used for 1 h incubation at room temperature. 413
Immunoblots were developed with enhanced chemiluminescence reagents (Millipore, 414 Billerica, MA, USA) and exposed to X-ray films. 415 416
Filter trap assays 417
Cells were pelleted by centrifugation at 700 g for 10 min and cell lysates collected in 418 native conditions as described above. One hundred µg of native protein extracts were 419 mixed with SDS to a final concentration of 0.4% (w/v). Samples were loaded on a 420 dot-blotting device and filtered by vacuum through cellulose acetate membranes (0.22 421 µm pore; GE Water & Process Technologies, Fairfield, CT, USA), previously 422 incubated with 1% (w/v) SDS solution in PBS. After filtration, membranes were 423 washed twice and processed for immublotting detection of HTT, as described above. 424
In these conditions, only large SDS-insoluble aggregates are retained in the filter and 425 therefore HTT signal is proportional to the presence of large insoluble species. 426
Analyses and quantification of blots signal were performed using ImageJ software. 427
HTTex1 aggregation levels (Fig 4) were calculated by densitometry analyses and 428 normalized to total HTT expression levels and GAPDH loading control. 429 430
Drosophila stocks, genetics and crosses 431
Flies were maintained at 25ºC and raised on standard cornmeal medium in a light/dark 432 cycle of 12 h. We generated eight constructs encoding for different versions of 433 HTTex1 fused to mCherry: a wild-type version with a polyQ tail containing 19 434 glutamines, a mutant version with 97 glutamines, and six constructs encoding 435 phosphomutant versions (T3A/D, S13A/D and S16A/D) with 97 glutamines. To 436 establish transgenic UAS-HTTex1-mCherry lines, our constructs were cloned into For confocal imaging of adult brains, 10-days-old flies were dissected and brains 466 prepared as previously described [51] . Briefly, adult flies were anesthetized with CO 2 467 and brains isolated in PBS 1X from the head cuticles before being fixed in 4% 468 DPP analysis was performed in living animals as previously described [51, 59] . 495
Briefly, flies at age of 1, 8 or 15 days were anaesthetized with CO 2 and then placed on 496 a 50 mm petri dish, previously poured with 2% (w/v) agarose at 40ºC. Once the 497 agarose was solidified, the anesthetized flies were covered with cool water to keep 498 anesthetic conditions. Adult compound eye integrity of at least 5 flies per genotype 499 was examined by fluorescence microscopy with a water immersion objective (HC 500 APO L40X/0.80W U-V-I, Leica Microsystems, Wetzlar, Germany). Images were 501 obtained using a Leica DM5500 B microscope (Leica Microsystems, Wetzlar, 502 Germany) and an Andor Luca R DL-604M camera (Andor Technology Ltd., Belfast, 503 UK). Images were analysed using Image J free software and number of fluorescing 504 rhabdomeres was scored for >15 ommatidia per fly. 505 506
Statistical analyses 507
GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA) or Sigmaplot 508 software (Systat Software, Inc., San Jose, CA, USA) were used to perform the 509 statistical analysis and graphical representation of data. In vitro results are shown as 510 the average ± standard deviation (SD) of at least 3 independent experiments and 511
Drosophila results as the average ± standard error (SEM), unless specified otherwise. 512
Cell culture data was analysed by means of a one-way ANOVA followed by a post-513 hoc Tukey test for average comparison. Aggregates quantification in Drosophila was 514 analysed by means of a one-way ANOVA with Newman-Keuls post-hoc test. DPP 515 assays were analysed by means of a two-way ANOVA followed by a Bonferroni post-516 hoc test. Results were in all cases considered significant only when p<0.05. 517 518 Network (EHDN). TFO is currently supported by the DFG Center for Nanoscale 525
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